Clinical Trial: Study of Panitumumab in the Treatment of Carcinoid Syndrome
Study Status: Withdrawn
Recruit Status: Withdrawn
Study Type: Interventional
Official Title: Phase II Study of Panitumumab in the Treatment of Carcinoid Syndrome
Brief Summary: The primary hypothesis of this study is that panitumumab, an inhibitor of the epidermal growth factor receptor (EGFR), is an effective treatment for carcinoid syndrome in people who fail or do not adequately respond to octreotide or other supportive therapies.
Detailed Summary:
Sponsor: Boston Medical Center
Current Primary Outcome:
- Radiographic measures [ Time Frame: Every 4 cycles ]
- Tumor Marker Evaluations [ Time Frame: Every 2 cycles ]
Original Primary Outcome: Same as current
Current Secondary Outcome: Quality of LIfe [ Time Frame: Day 1 each cycle and 1 month follow-up ]
Original Secondary Outcome: Same as current
Information By: Boston Medical Center
Dates:
Date Received: July 28, 2010
Date Started: July 2013
Date Completion:
Last Updated: July 25, 2013
Last Verified: July 2013
